Verve Therapeutics, Inc. (NASDAQ:VERV) Given Consensus Recommendation of “Buy” by Analysts
Verve Therapeutics, Inc. (NASDAQ:VERV – Get Free Report) has been assigned a consensus recommendation of “Buy” from the six research firms that are currently covering the firm, MarketBeat.com reports. Six investment analysts have rated the stock with a buy rating. The average twelve-month price objective among brokers that have updated their coverage on the stock […]
Verve Therapeutics, Inc. (NASDAQ:VERV – Get Free Report) has been assigned a consensus recommendation of “Buy” from the six research firms that are currently covering the firm, MarketBeat.com reports. Six investment analysts have rated the stock with a buy rating. The average twelve-month price objective among brokers that have updated their coverage on the stock […]
